𡽽ŕŔÚ English
Aims and scope Subscription Info for authors Editorial Board Contacts
International journal of Immunopathology, allergology, infectology.

Intradermal allergen immunotherapy in atopic bronchial asthma

VykhristsenkÓ L.R.

Vitebsk Medical University, Vitebsk, Belarus

The purpose of research - a comparative evaluation of the efficacy and safety of accelerated intradermal or subcutaneous allergen immunotherapy method (ASIT) in patients with atopic asthma (ABA).
Methods: A randomized, open, prospective study of parallel groups. The study involved 105 patients. 1st group (54) received intradermal ASIT of standardized house dust allergen accelerated scheme (a set period of allergen dose - 14 days), group 2 (51) received subcutaneous ASIT. ASIT duration - 3 years. Evaluated the frequency of asthma symptoms, the effectiveness of treatment by the physician and the patient, the dynamics of skin sensitization, safety.
Results: 3-year course of intradermal ASIT is more efficient compared with subcutaneous ASIT, which was confirmed by a decrease in the frequency of asthma symptoms by 34.4%, whereas in subcutaneous ASIT - 29% (p1-2 <0.05), greater than the number (p1-2 = 0.02) and a smaller number of satisfactory results (p1-2 = 0.03). Mild systemic side effects of intradermal ASIT observed in 29% (16/54) of patients, for subcutaneous ASIT - 41% (21/51) patients (p> 0,05), the duration was more systemic reactions for subcutaneous ASIT (p1-2 <0.05). Under intradermal ASIT revealed a higher patient compliance to treatment.
Conclusions: intradermal express ASIT is effective and safe, the best results compared with subcutaneous ASIT achieved when it is used for 3 years.

Keywords

Atopic bronchial asthma, ňfficacy, safety.

Fulltext in PDF

Open file
Size: 476 KB

Reference

VykhristsenkÓ L.R. Immunopathology, allergology, infectology 2014; 3:21-28